Insilico Medicine, a clinical stage artificial intelligence (AI)-powered drug discovery company, is set to tackle key issues in AI drug discovery at the upcoming BIO International Convention in San Diego from June 3-6. The company’s leadership, including Chief Business Officer Michelle Chen, PhD; Vice President for Business Development Keith Mikule, PhD; Head of Business Development, APAC Jue Wang, PhD; and President of Insilico Medicine Taiwan Jimmy Yen-Chu Lin, PhD, will be present to discuss Insilico’s latest pipeline developments.
Advancing AI Drug Discovery
At the convention, Insilico will showcase its groundbreaking pipeline, which features over 30 AI-designed small molecule inhibitors targeting diseases such as cancer, inflammatory bowel disease, and fibrosis. With seven candidates already in clinical stages, Insilico’s innovative approach holds promise for therapeutic advancements. The company’s representatives will be available at Booth #5657 to engage in discussions about their pioneering research and potential licensing opportunities.
Insilico Medicine – 10 Years of AI Drug Discovery Innovation
Insightful Panel Discussions
Insilico’s participation in the convention includes panel discussions featuring prominent industry leaders. On June 3, Insilico’s Vice President and Global Head of AI Platforms Petrina Kamya, PhD, will speak on the panel “The Use of AI in mRNA: The New Revolution?” alongside experts from McGill University, J.P. Morgan, Moderna, and Sanofi. The discussion will explore the role of AI in therapeutic advances, particularly in infectious disease, oncology, and clinical trials.
On June 4, Insilico’s founder and CEO Alex Zhavoronkov, PhD, will contribute to the panel “AI’s Trial by Fire: Experimental Validation in Drug Discovery.” Joined by leaders from the Alliance for AI in Healthcare, Envisagenics, Johnson & Johnson, and AstraZeneca, Dr. Zhavoronkov will discuss how AI drug discovery is revolutionizing and the importance of rigorous experimental validation in bridging AI’s predictions with real-world applications.
Driving Innovation in Drug Development
Insilico Medicine has been at the forefront of using generative AI for drug discovery since 2016. The company’s pioneering work has led to the development of a robust pipeline of therapeutic assets across various disease areas, including fibrosis, cancer, immunology, and aging-related diseases. Notably, Insilico recently published a paper in Nature Biotechnology detailing the preclinical and clinical evaluation of its lead drug—a potential first-in-class TNIK inhibitor for idiopathic pulmonary fibrosis. With a comprehensive portfolio of over 30 assets and significant progress in clinical development, Insilico continues to drive innovation in AI-powered drug discovery.
